T cells RNA silencing guide

T cells present unique biological barriers that can make conventional transfection methods underperform or fail:

Lipofection-induced toxicity

Cationic lipid-based transfection reagents show poor efficiency and induce cell death in T cells, reducing cell viability after transfection. This toxicity is particularly problematic for functional assays requiring viable effector T cells.

Dependence on activation state

Conventional transfection can be less efficient in resting T cells than in activated ones. Activation with anti-CD3/CD28 increases endocytosis, creating a narrow 24-48h window for lipofection. Outside this window, transfection efficiency falls, which is what makes resting and memory T cell populations hard to reach by that route.

Phenotype and functional alteration

Electroporation causes plasma membrane disruption that fundamentally alters T cell biology. A functional readout taken afterwards can then carry the delivery's effect rather than the target's.

Donor-to-donor variability

Primary human T cells from different donors vary in transfection efficiency with conventional methods. This variability stems from differences in activation state, memory phenotype distribution, and intrinsic membrane properties, requiring extensive optimization for each donor.

Viral vector barriers

Viral vectors for CAR-T and adoptive cell therapies face regulatory scrutiny, high production costs, and potential insertional mutagenesis risks. Manufacturing timelines of 2-4 weeks for lentiviral production limit clinical scalability.

Immunogenic activation and experimental artifacts

Transfection reagents, particularly cationic lipids and viral vectors, trigger innate immune responses through TLR activation in T cells. This creates experimental artifacts, because the delivery step itself activates the cells. Pattern recognition receptor engagement alters baseline cytokine profiles, activation markers, and metabolic states, which can make a target-specific phenotype difficult to separate from a delivery-induced one.

Method comparison

Gene silencing in T cells with no transfection reagent

Uptake and target engagement in T cells

Key benefits

• Zero transfection required. Add to the culture medium. No lipids, no electroporation, no viral vectors, so the cationic lipid that exacerbates activation-induced cell death (AICD) is not introduced. Viability is preserved and target-dependent; empirical validation is required.
• Knockdown efficiency. Typically 70-95% knockdown. Gene silencing across diverse T cell types: primary CD3+, CD4+, CD8+, Tregs, activated T cells, and cell lines (Jurkat, MOLT-4).
• T cell function in functional assays. No cationic lipid is added and no pulse is applied, so the delivery step brings neither the toxicity nor the membrane disruption that alter T cell function. Read proliferation (CFSE dilution), cytokine production (IFN-γ, IL-2, TNF-α) and cytotoxic activity against the non-targeting control.
• Consistent across donors. The same protocol is used across PBMC donors, HLA types, and memory and naive subsets.
• Rapid timeline. No cloning, no virus production. Design and synthesis in 10-14 business days, then 24-72 hours post-treatment for mRNA knockdown.
• Scalable for CAR-T research. AUMsilence sdASOs are added to the culture medium. Compatible with large-scale T cell expansion protocols. No equipment is required.

Cell types and applications

• Primary human T cells (CD3+, CD4+, CD8+, Tregs)
• CAR-T cell engineering and optimization
• Tumor-infiltrating lymphocyte (TIL) therapy
• Immune checkpoint silencing (PD-1, CTLA-4, LAG-3, TIM-3)
• T cell exhaustion and dysfunction studies
• Cytokine modulation (IL-2, IFN-γ, TNF-α, IL-10)
• Transcription factor studies (FOXP3, T-bet, GATA3, RORγt)
• Functional screening in Jurkat, MOLT-4, or other T cell lines
• Co-culture and cytotoxicity assays

Alternative products

• AUMsilence™ sdASO™
• AUMantagomir™ sdASO™
• AUMlnc™ sdASO™

Cell-type-optimized protocols for primary T cells, T cell lines, and activated T cells. No transfection reagents required.

Quick start protocol (all T cell types)

1. 01Culture T cells at 0.5-1 × 10⁶ cells/mL in appropriate medium
2. 02Add AUMsilence™ sdASO™ directly to culture medium at 10 μM, dialing up or down within 5-20 μM as the target needs (no transfection reagent)
3. 03Incubate 48-72 hours at 37°C, 5% CO₂
4. 04Validate knockdown by qRT-PCR (mRNA) and flow cytometry or Western blot (protein)

Cell-type-specific protocols

Used for freshly isolated PBMCs or cryopreserved T cells

1. 01

   Step 1: T cell isolation

   Isolate CD3+ T cells from PBMCs using negative selection (magnetic bead-based isolation kit). Negative selection preserves surface markers and activation state.
   Materials: RPMI-1640 + 10% FBS + 1% Pen/Strep + 2 mM L-glutamine + 50 μM β-mercaptoethanol
   Note: Avoid positive selection (anti-CD3 beads) if studying TCR signaling
   Timing: Day 0
2. 02

   Step 2: Cell seeding

   Seed T cells at 0.5-1 × 10⁶ cells/mL in 24-well plate (500 μL/well) or appropriate culture vessel. Use complete RPMI-1640 medium.
   Materials: 24-well plate, complete RPMI-1640
   Note: T cells prefer suspension culture at this density range
   Timing: Day 0
3. 03

   Step 3: AUMsilence sdASO treatment

   Add AUMsilence sdASO directly to culture medium at 10 μM final concentration. Calculate volume: For 500 μL culture, add 5 μL of 1 mM AUMsilence sdASO stock. Mix gently by pipetting. Note: The recommended working range is 5-20 μM, with a starting concentration of 10 μM. How much is needed depends on cell doubling time and target gene stability.
   Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)
   Note: No media change or washing required.
   Timing: Day 0 or Day 1
4. 04

   Step 4: Incubation

   Incubate at 37°C, 5% CO₂ for 48-72 hours. Monitor cell density; split if exceeding 2 × 10⁶ cells/mL.
   Materials: Humidified incubator
   Note: Knockdown is typically achieved 24-72 hours after treatment. Harvest at several points inside that window for a time course.
   Timing: Days 0-3
5. 05

   Step 5: Validation

   Harvest cells by centrifugation. For mRNA: qRT-PCR, typically 70-95% knockdown. For protein: flow cytometry (surface markers) or Western blot (intracellular proteins).
   Materials: RNA extraction kit, qPCR reagents, antibodies
   Note: Include viability staining (7-AAD or fixable viability dye). Viability is target-dependent and needs empirical validation.
   Timing: Days 2-3

For studying effector T cell function and cytokine production

1. 01

   Step 1: T cell activation

   Stimulate isolated T cells with plate-bound anti-CD3 (5 μg/mL) + soluble anti-CD28 (2 μg/mL) or magnetic CD3/CD28 activation beads (1:1 bead-to-cell ratio). Culture at 1 × 10⁶ cells/mL.
   Materials: Anti-CD3/CD28 antibodies or activation beads, complete RPMI + IL-2 (50-100 U/mL)
   Note: Activation increases metabolic activity and enhances ASO uptake
   Timing: Day -1 (24h before ASO treatment)
2. 02

   Step 2: AUMsilence sdASO treatment (post-activation)

   At 24h post-activation, add AUMsilence sdASO directly to activated T cells at 10 μM. No media change needed. Beads remain in culture. The recommended working range is 5-20 μM, with a starting concentration of 10 μM. How much is needed depends on target gene half-life and cell doubling time.
   Materials: AUMsilence sdASO
   Note: Treat the non-targeting control at the same point after activation, since activation increases endocytosis, which is the route of uptake
   Timing: Day 0
3. 03

   Step 3: Functional assays

   At 48-72h post-ASO treatment, perform functional assays: cytokine ELISA (IFN-γ, IL-2, TNF-α), proliferation (CFSE dilution), cytotoxicity assays.
   Materials: ELISA kits, flow cytometry antibodies
   Note: Read proliferation and cytokine production against the non-targeting control, which is what shows whether a change in either is on target
   Timing: Days 2-3

Immortalized T cell line for high-throughput screening

1. 01

   Step 1: Cell culture

   Culture Jurkat cells in RPMI-1640 + 10% FBS. Maintain log-phase growth (3-8 × 10⁵ cells/mL). Split cells to 3 × 10⁵ cells/mL 24h before ASO treatment.
   Materials: Complete RPMI-1640
   Note: Jurkat cells double every 20-24 hours
   Timing: Day -1
2. 02

   Step 2: AUMsilence sdASO treatment

   Add AUMsilence sdASO at 10 μM to Jurkat cultures.
   Materials: AUMsilence sdASO
   Note: Measure knockdown in Jurkat cells at 48h
   Timing: Day 0
3. 03

   Step 3: Analysis

   Harvest at 48h for qRT-PCR and flow cytometry. Jurkat cells useful for TCR signaling studies (PLC-γ1, ZAP70, LAT knockdown).
   Materials: Standard molecular biology reagents
   Note: Immortalized lines show less donor variability than primary cells
   Timing: Day 2

Essential controls

• Untreated T cells: Baseline expression levels and viability
  Culture identically but without ASO addition
• Non-targeting control ASO: Control for off-target effects and ASO-related toxicity
  Use AUM non-targeting control at same concentration (10 μM or match experimental concentration)
• Positive control (housekeeping gene): Verify ASO uptake and RNase H1 activity
  Optional: Use GAPDH or ACTB-targeting ASO to confirm knockdown

Optimization strategies

• ASO concentration
  Recommendation: Start at 10 μM as the standard concentration. Dial down for sensitive targets or up for highly stable genes.
  Rationale: The recommended working range is 5-20 μM, with a starting concentration of 10 μM. How much is needed depends on target gene half-life and cell doubling time. Rapidly dividing cells or highly stable transcripts may require higher concentrations.
• Incubation time
  Recommendation: 48-72h for most applications. 24h for early time-point analysis.
  Rationale: mRNA knockdown is typically achieved 24-72 hours after treatment. Where the target protein is long-lived, a later time point may be required.
• Cell density
  Recommendation: Maintain 0.5-1.5 × 10⁶ cells/mL.
  Rationale: T cells compete for ASO at high density. Very low density (<3 × 10⁵/mL) may reduce viability.
• Medium composition
  Recommendation: Standard RPMI + 10% FBS is optimal.
  Rationale: AUMsilence sdASO is added to serum-containing medium with no media change. Serum proteins may reduce uptake.
• ASO sequence selection
  Recommendation: Design and test 3-5 ASOs targeting different regions of the target mRNA. Select the sequence with highest knockdown efficiency for downstream experiments.
  Rationale: Knockdown efficiency varies with the target site, because of RNA secondary structure, protein binding and accessibility. Testing multiple sequences identifies the optimal ASO. Target regions with low predicted secondary structure (ΔG > -10 kcal/mol) and avoid highly structured domains or protein binding sites when possible.

Troubleshooting

Quantitative RT-PCR (qRT-PCR)

Flow cytometry

Western blot

ELISA (cytokine secretion)

Functional assays

• Proliferation (CFSE dilution)
  Protocol: Label T cells with CFSE before AUMsilence sdASO treatment. Stimulate with anti-CD3/CD28. Analyze CFSE dilution by flow cytometry at 72-96h.
  Interpretation: Reduced proliferation if targeting pro-proliferative genes (IL-2, CD28, mTOR pathway).
• Cytotoxicity assay
  Protocol: Co-culture knockdown T cells with target cells (tumor lines or peptide-loaded cells). Measure target cell lysis by LDH release, CFSE dilution, or flow-based viability.
  Interpretation: Reduced killing if targeting perforin, granzyme B, or FasL. The checkpoint receptors PD-1 and CTLA-4 restrain T cell activation, so for a checkpoint target read killing against the non-targeting control.
• Apoptosis (Annexin V / 7-AAD)
  Protocol: Stain with Annexin V and 7-AAD at 48-96h. Analyze by flow cytometry.
  Interpretation: Increased apoptosis if targeting pro-survival genes (BCL2, MCL1). Decreased apoptosis if targeting Fas or FasL.
• Activation markers (CD25, CD69, CD71)
  Protocol: Stimulate T cells post-knockdown. Measure CD25, CD69, CD71 expression by flow cytometry.
  Interpretation: Reduced activation if targeting TCR signaling or co-stimulatory molecules.

Critical controls for validation

• Untreated T cells
  Purpose: Baseline for all measurements
  Culture identically to treated cells without ASO addition.
• Non-targeting control ASO
  Purpose: Control for ASO-specific effects (off-target, immune stimulation)
  Use AUM non-targeting control ASO at same concentration and timing as experimental ASO.
• Positive control ASO
  Purpose: Verify ASO uptake and activity
  Optional but recommended: Use GAPDH or ACTB-targeting ASO to confirm knockdown.
• Viability control
  Purpose: Ensure cell health throughout experiment
  Include viability staining (7-AAD or fixable viability dye) in all flow cytometry panels.
• Dose-response verification
  Purpose: Confirm concentration-dependent knockdown and rule out saturation effects
  Test at minimum 3 concentrations (e.g., 5 μM, 10 μM and 20 μM AUMsilence sdASO). Knockdown should correlate with concentration. Absence of dose-dependency suggests off-target or non-specific effects. Essential for establishing optimal working concentration. Note: The recommended working range is 5-20 μM, with a starting concentration of 10 μM. How much is needed depends on cell doubling time and target gene stability.
• Independent ASO verification
  Purpose: Confirm target specificity with second independent ASO sequence
  Use 3-5 different ASOs targeting non-overlapping regions of the same mRNA. Concordant knockdown across independent sequences confirms on-target specificity and eliminates sequence-specific off-target effects. This is the gold standard for target validation.

Best practices

• Use biological triplicates (n=3 independent experiments) for statistical analysis
• Validate knockdown at both mRNA (qRT-PCR) and protein (flow cytometry or Western blot) levels
• Include time-course experiments for targets with unknown mRNA/protein half-lives
• For functional assays, verify knockdown in the same cells used for functional readout
• Report both knockdown efficiency and cell viability in all publications
• Use appropriate statistical tests (t-test, ANOVA) with p<0.05 threshold